Samsung Bioepis gets EC's approval for Opuviz

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

Celltrion applies for approval in US for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...

Kwangdong introduces new drug candidate for pediatric myopia

South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it has signed a contract with Hong Kong-based Zhaoke Ophthalmo...

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...

Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...

Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe

South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...